News & Updates

Show Multimedia Only

Iruplinalkib trumps crizotinib for ALK TKI-naïve NSCLC

02 Oct 2023 by

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

02 Oct 2023

Acetazolamide helps patients with COPD reach new peaks

02 Oct 2023 by

Acetazolamide helps to reduce the chances of altitude-related adverse health effects (ARAHE) in patients with chronic obstructive pulmonary disease (COPD) in a study reported at ERS.

02 Oct 2023

Pretreatment serum CEA level predicts survival in NSCLC

29 Sep 2023

Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.

29 Sep 2023

Tacrolimus or cyclosporine for CLAD: The better of 2 immunosuppressants

28 Sep 2023 by

Tacrolimus given once daily significantly reduced the 3-year incidence of chronic lung allograft dysfunction (CLAD) in lung transplant patients compared with standard immunosuppressant in the open label, multicentre, ScanCLAD trial presented at ERS 2023.

28 Sep 2023

Atezolizumab-chemo confers durable survival benefit in ES-SCLC

27 Sep 2023 by

In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).

27 Sep 2023

Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?

26 Sep 2023 by

A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.

26 Sep 2023

Dupilumab improves lung function in children with moderate-to-severe type 2 asthma

26 Sep 2023 by

Treatment with dupilumab significantly improved lung function in children with moderate-to-severe type 2 asthma compared with placebo, according to two post hoc analyses presented at ERS 2023.

26 Sep 2023

Is CPAP cardioprotective?

25 Sep 2023 by

Two studies presented at ERS 2023 demonstrated the potential of a continuous positive airway pressure (CPAP) machine to address cardiovascular (CV) risks in individuals with obstructive sleep apnoea (OSA).

25 Sep 2023

Vaping tied to chronic stress, poor QoL in young adults

23 Sep 2023 by

Use of e-cigarette (EC) shows a significant relation with a higher incidence of chronic stress and is indicative of poorer quality of life (QoL) in young adults, suggests a study presented at ERS 2023.

23 Sep 2023

Fatigue in COPD influenced by multiple contributing factors

22 Sep 2023 by

Fatigue in people with chronic obstructive pulmonary disease (COPD) may be caused by factors such as shortness of breath, sleep quality, pain, and fatigue-related catastrophizing, according to the FAntasTIGUE study.

22 Sep 2023